Jan Aushadhi scheme has led to savings of Rs 7,416 cr for citizens this fiscal: Govt

New Delhi: The over 10,000 Jan Aushadhi Kendras across the country have led to savings of around Rs 7,416 crore for the citizens this financial year, Rajya Sabha was informed on Friday. In a written reply in the Upper House, Minister of State for Chemicals and Fertilisers Bhagwanth Khuba said an unprecedented 150 times growth in annual sales has been witnessed by the scheme in the last 9 years.

“During the financial year 2022-23, Pharmaceuticals & Medical Devices Bureau of India (PMBI) has sold Jan Aushadhi medicines worth Rs 1,236 crore, with approx 40 per cent growth from the previous year and this has led to savings of approximately Rs 7,416 crore to the citizens,” he noted.

The projected sales target for 2023-24 is Rs 1,400 crore and the scheme is growing at a very fast pace garnering public trust and confidence, Khuba said.

In all, during the past nine years, total savings have been estimated at more than Rs 23,000 crore for the citizens under this scheme, he stated.

On an average 10-12 lakh people visit Jan Aushadhi Kendras (JAKs) daily, the minister said. Khuba stated that as on November 30 this year, 10,006 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) have been opened covering 753 districts across the country.

Replying to a separate question, Khuba said India’s total import of active pharmaceutical ingredients (APIs) for 2022-23 is worth Rs 36,229.15 crore and the quantity is 4,02,111.18 metric tonnes.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’